SEC filings and other documents

Strong revenue growth, pipeline advances, and DTC strategies drive long-term outlook.

Strong revenue growth, pipeline advances, and disciplined investment drive long-term outlook.

Q2 2026 revenue grew 10% to $10B, with raised guidance and strong growth across key products.

Key growth drivers and pipeline advances position the company for sustained performance through 2026.

Key products and pipeline advances drive growth, with AI boosting efficiency and market readiness.

Key products and pipeline assets drive growth, with major investments and strong Q1 results.

Key growth drivers delivered 24% sales growth, supporting raised 2026 revenue and EPS guidance.

Double-digit growth, pipeline advances, and strategic M&A position for sustained expansion.

Double-digit growth, pipeline innovation, and access strategies drive long-term momentum.

Transformative oncology therapies and AI-driven innovation drive pipeline and clinical expansion.

Advancing late-stage trials and expanding TSLP-targeted therapies, with major data readouts ahead.

2026 growth will be fueled by innovative therapies, pipeline advances, and disciplined execution.

2025 saw double-digit growth and record sales, with 2026 set for further expansion amid biosimilar headwinds.

Momentum in growth drivers and pipeline, with strong R&D and rare disease expansion.

Six growth drivers and a robust pipeline underpin strong momentum and future growth.

Q3 revenue up 12% to $9.6B; raised 2025 guidance amid strong product and pipeline momentum.

Q2 growth, pipeline progress, and U.S. investments position for long-term innovation and expansion.